Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Manopla v. Lexicon Pharmaceuticals, Inc. et al
Case Number:
4:19-cv-00301
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
August 17, 2020
Lexicon Pharma Ditches Investor Suit Over Diabetes Drug
A Texas federal judge said Friday that it would be futile for investors who'd already "pleaded their best case" to amend claims that Lexicon Pharmaceuticals overpromised on its ability to bring a new diabetes drug to market.
-
June 04, 2019
Pomerantz To Lead Lexicon Pharmaceuticals Securities Suit
A Texas federal judge has ordered the Pomerantz Law Firm to serve as lead counsel in shareholders' proposed class action accusing Lexicon Pharmaceuticals of promising more than it could deliver in bringing its diabetes drug Zynquista to market.